Amarin Corporation PLC Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (38)

Latest Posts

About This Stock More About This Stock
Amarin Settlement With Apotex An 'Incremental Positive,' Says Stifel
Article By: The Fly
Wednesday, June 17, 2020 11:09 AM EDT
Stifel analyst Derek Archila reiterates his Hold rating on Amarin shares after the company settled with Apotex regarding its ANDA application for generic Vascepa.
In this article: AMRN Also: RDY, TEVA
Read
Hikma Receives FDA Approval For Generic Of Amarin's Vascepa
Article By: The Fly
Friday, May 22, 2020 7:42 AM EDT
Hikma Pharmaceuticals announced overnight that its wholly owned U.S. subsidiary Hikma Pharmaceuticals USA has received approval from the Food and Drug Administration for its Icosapent Ethyl Capsules, the generic equivalent to Amarin's Vascepa.
In this article: HKMPF, AMRN
Read
Northland Starts Amarin At Outperform Amid 'Major Paradigm Shift'
Article By: The Fly
Tuesday, May 5, 2020 11:00 AM EDT
Northland analyst Carl Byrnes initiated coverage of Amarin with an Outperform rating and $15 price target.
In this article: AMRN
Read
Amarin A 'Strong Buy' Ahead Of Federal Circuit Ruling, Says Roth Capital
Article By: The Fly
Monday, May 4, 2020 10:07 AM EDT
Roth Capital analyst Yasmeen Rahimi sees COVID-19 disruptions as only a "minor distraction" from Amarin's continued commercial rollout of Vascepa.
In this article: AMRN
Read
The Week Ahead In Biotech: Urogen FDA Decision, Amarin, J&J Earnings And More COVID-19 Updates
Article By: Benzinga
Sunday, April 12, 2020 1:22 PM EDT
Biotech stocks moved higher last week along with the broader market. The week witnessed a few clinical readouts and pre-announcements that reflected the coronavirus (COVID-19) impact.
In this article: ABT, JNJ, ALNY, GILD, ISRG, AMRN, AXSM, SCYX, ASND, URGN, ITRM, OVID, VIR
Read

PARTNER HEADLINES

Latest Tweets for $AMRN

No tweets yet!